Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

That has to be a back-and-forth discussion. The second thing is, given that we have all of these therapies for ulcerative colitis, we do have choices. And you can use both that information ...

another. Patients that are more likely to go on to colectomy for ulcerative colitis vs. another high-risk patients, that we may have overlooked, or high-risk factors that we may have overlooked ...

If you’re living with ulcerative colitis, testing may help identify which foods bother you, so that you can cut them out of your diet. Ulcerative colitis (UC) cannot cause a food allergy ...

Coverage for ulcerative colitis specialists and treatment can depend on your specific health insurance plan and whether healthcare professionals are in your network. Planning for the future with a ...